Compile Data Set for Download or QSAR

Found 36 hits Enz. Inhib. hit(s) with all data for entry = 9724   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484071 ((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...) Show SMILES O[C@@H](CN[C@H]1COC2(C1)CCN(CC2)S(=O)(=O)c1ccc2cc[nH]c2c1)COc1cccc(c1)S(=O)(=O)C1CC1 |r| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484061 ((2S)-1-(3-(1- fluoroethylsulfonyl) phenoxy)-3-((R)...) Show SMILES CC(F)S(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2ccc3ncccc3c2)c1 |r| Show InChI InChI=1S/C28H34FN3O7S2/c1-20(29)40(34,35)25-6-2-5-24(15-25)38-19-23(33)17-31-22-16-28(39-18-22)9-12-32(13-10-28)41(36,37)26-7-8-27-21(14-26)4-3-11-30-27/h2-8,11,14-15,20,22-23,31,33H,9-10,12-13,16-19H2,1H3/t20?,22-,23+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.02E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484073 ((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...) Show SMILES CS(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cnc3cc[nH]c3c2)c1 |r| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.12E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484058 ((S)-1-((S)-8-(4'- (aminomethyl)-5- methoxybiphenyl...) Show SMILES COc1cc(cc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2CC2)CC1)-c1ccc(CN)cc1 |r| Show InChI InChI=1S/C34H43N3O8S2/c1-43-30-15-26(25-7-5-24(20-35)6-8-25)16-33(18-30)47(41,42)37-13-11-34(12-14-37)19-27(22-45-34)36-21-28(38)23-44-29-3-2-4-32(17-29)46(39,40)31-9-10-31/h2-8,15-18,27-28,31,36,38H,9-14,19-23,35H2,1H3/t27-,28-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.16E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484059 ((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...) Show SMILES CCOc1ccc(cc1S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)COC)CC1)-c1ccc(CN)cc1 |r| Show InChI InChI=1S/C34H45N3O9S2/c1-3-44-32-12-11-27(26-9-7-25(20-35)8-10-26)17-33(32)48(41,42)37-15-13-34(14-16-37)19-28(22-46-34)36-21-29(38)23-45-30-5-4-6-31(18-30)47(39,40)24-43-2/h4-12,17-18,28-29,36,38H,3,13-16,19-24,35H2,1-2H3/t28-,29-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.50E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484060 ((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...) Show SMILES CCOc1ccc(cc1S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C(C)C)CC1)-c1ccc(CN)cc1 |r| Show InChI InChI=1S/C35H47N3O8S2/c1-4-44-33-13-12-28(27-10-8-26(21-36)9-11-27)18-34(33)48(42,43)38-16-14-35(15-17-38)20-29(23-46-35)37-22-30(39)24-45-31-6-5-7-32(19-31)47(40,41)25(2)3/h5-13,18-19,25,29-30,37,39H,4,14-17,20-24,36H2,1-3H3/t29-,30-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.66E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484076 (3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...) Show SMILES O[C@@H](CN[C@H]1COC2(C1)CCN(CC2)S(=O)(=O)c1c[nH]c2ccccc2c1=O)COc1cccc(c1)S(=O)(=O)C1CC1 |r| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.73E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484050 ((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...) Show SMILES CCOc1ccc(cc1S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1)-c1ccc(CN)cc1 |r| Show InChI InChI=1S/C36H47N3O9S2/c1-2-46-33-11-10-28(27-8-6-26(21-37)7-9-27)18-34(33)50(44,45)39-16-14-35(15-17-39)20-29(23-48-35)38-22-30(41)24-47-31-4-3-5-32(19-31)49(42,43)36(25-40)12-13-36/h3-11,18-19,29-30,38,40-41H,2,12-17,20-25,37H2,1H3/t29-,30-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.73E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484051 ((S)-1-((R)-8-(4'- (aminomethyl)-4- fluorobiphenyl-...) Show SMILES NCc1ccc(cc1)-c1ccc(F)c(c1)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C34H42FN3O8S2/c35-31-9-8-26(25-6-4-24(19-36)5-7-25)16-32(31)48(43,44)38-14-12-33(13-15-38)18-27(21-46-33)37-20-28(40)22-45-29-2-1-3-30(17-29)47(41,42)34(23-39)10-11-34/h1-9,16-17,27-28,37,39-40H,10-15,18-23,36H2/t27-,28+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.75E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484048 ((S)-1-(3-(cyclopropyl- sulfonyl)phenoxy)- 3-((R)-8...) Show SMILES CN1CCOc2ncc(cc12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2CC2)CC1 |r| Show InChI InChI=1S/C28H38N4O8S2/c1-31-11-12-38-27-26(31)14-25(17-30-27)42(36,37)32-9-7-28(8-10-32)15-20(18-40-28)29-16-21(33)19-39-22-3-2-4-24(13-22)41(34,35)23-5-6-23/h2-4,13-14,17,20-21,23,29,33H,5-12,15-16,18-19H2,1H3/t20-,21+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.75E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484073 ((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...) Show SMILES CS(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cnc3cc[nH]c3c2)c1 |r| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.78E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484057 ((S)-1-((S)-8-(4'- (aminomethyl)-6- methoxybiphenyl...) Show SMILES COc1ccc(cc1-c1ccc(CN)cc1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2CC2)CC1 |r| Show InChI InChI=1S/C34H43N3O8S2/c1-43-33-12-11-31(18-32(33)25-7-5-24(20-35)6-8-25)47(41,42)37-15-13-34(14-16-37)19-26(22-45-34)36-21-27(38)23-44-28-3-2-4-30(17-28)46(39,40)29-9-10-29/h2-8,11-12,17-18,26-27,29,36,38H,9-10,13-16,19-23,35H2,1H3/t26-,27-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.79E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484066 ((S)-1-((S)-8-(4'- ((butylamino)methyl) biphenyl-3-...) Show SMILES CCCCNCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C38H51N3O8S2/c1-2-3-18-39-24-29-10-12-30(13-11-29)31-6-4-9-36(21-31)51(46,47)41-19-16-37(17-20-41)23-32(26-49-37)40-25-33(43)27-48-34-7-5-8-35(22-34)50(44,45)38(28-42)14-15-38/h4-13,21-22,32-33,39-40,42-43H,2-3,14-20,23-28H2,1H3/t32-,33-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.84E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484047 ((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...) Show SMILES OCC1(CC1)S(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cnc3ccccc3c2)c1 |r| Show InChI InChI=1S/C30H37N3O8S2/c34-21-30(8-9-30)42(36,37)26-6-3-5-25(15-26)40-20-24(35)17-31-23-16-29(41-19-23)10-12-33(13-11-29)43(38,39)27-14-22-4-1-2-7-28(22)32-18-27/h1-7,14-15,18,23-24,31,34-35H,8-13,16-17,19-21H2/t23-,24+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.88E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484070 ((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...) Show SMILES OCC1(CC1)S(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2ccc3ccccc3c2)c1 |r| Show InChI InChI=1S/C31H38N2O8S2/c34-22-31(10-11-31)42(36,37)28-7-3-6-27(17-28)40-21-26(35)19-32-25-18-30(41-20-25)12-14-33(15-13-30)43(38,39)29-9-8-23-4-1-2-5-24(23)16-29/h1-9,16-17,25-26,32,34-35H,10-15,18-22H2/t25-,26+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.04E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484063 ((S)-1-(3-(1- (hydroxymelhyl) cyclopropylsulfonyl) ...) Show SMILES CCC(C)(C)NCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C39H53N3O8S2/c1-4-37(2,3)41-24-29-11-13-30(14-12-29)31-7-5-10-36(21-31)52(47,48)42-19-17-38(18-20-42)23-32(26-50-38)40-25-33(44)27-49-34-8-6-9-35(22-34)51(45,46)39(28-43)15-16-39/h5-14,21-22,32-33,40-41,43-44H,4,15-20,23-28H2,1-3H3/t32-,33-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.11E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484049 ((S)-1-((R)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...) Show SMILES CCOc1ccc(cc1S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C(F)(F)CO)CC1)-c1ccc(CN)cc1 |r| Show InChI InChI=1S/C34H43F2N3O9S2/c1-2-46-31-11-10-26(25-8-6-24(19-37)7-9-25)16-32(31)50(44,45)39-14-12-33(13-15-39)18-27(21-48-33)38-20-28(41)22-47-29-4-3-5-30(17-29)49(42,43)34(35,36)23-40/h3-11,16-17,27-28,38,40-41H,2,12-15,18-23,37H2,1H3/t27-,28+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.11E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484075 (1-ethyl-8-fluoro-3-((R)- 3-((S)-2-hydroxy-3-(3- (m...) Show SMILES CCn1cc(c(=O)c2cccc(F)c12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(C)(=O)=O)CC1 |r| Show InChI InChI=1S/C29H36FN3O8S2/c1-3-32-17-26(28(35)24-8-5-9-25(30)27(24)32)43(38,39)33-12-10-29(11-13-33)15-20(18-41-29)31-16-21(34)19-40-22-6-4-7-23(14-22)42(2,36)37/h4-9,14,17,20-21,31,34H,3,10-13,15-16,18-19H2,1-2H3/t20-,21+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.18E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484053 ((S)-1-((S)-8-(4'-(2- aminoethyl)biphenyl-3- ylsulf...) Show SMILES NCCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C(F)(F)CO)CC1 |r| Show InChI InChI=1S/C33H41F2N3O8S2/c34-33(35,23-39)47(41,42)30-5-2-4-29(18-30)45-22-28(40)20-37-27-19-32(46-21-27)12-15-38(16-13-32)48(43,44)31-6-1-3-26(17-31)25-9-7-24(8-10-25)11-14-36/h1-10,17-18,27-28,37,39-40H,11-16,19-23,36H2/t27-,28-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.24E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484052 ((S)-1-((R)-8-(4'-(1- aminocyclopropyl)-6- methoxyb...) Show SMILES COc1ccc(cc1-c1ccc(cc1)C1(N)CC1)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C37H47N3O9S2/c1-47-34-10-9-32(20-33(34)26-5-7-27(8-6-26)37(38)13-14-37)51(45,46)40-17-15-35(16-18-40)21-28(23-49-35)39-22-29(42)24-48-30-3-2-4-31(19-30)50(43,44)36(25-41)11-12-36/h2-10,19-20,28-29,39,41-42H,11-18,21-25,38H2,1H3/t28-,29+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.50E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484045 ((S)-1-(3-(2- hydroxyethylsulfonyl) phenoxy)-3-(R)-...) Show SMILES OCCS(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cnc3ccccc3c2)c1 |r| Show InChI InChI=1S/C28H35N3O8S2/c32-12-13-40(34,35)25-6-3-5-24(15-25)38-20-23(33)17-29-22-16-28(39-19-22)8-10-31(11-9-28)41(36,37)26-14-21-4-1-2-7-27(21)30-18-26/h1-7,14-15,18,22-23,29,32-33H,8-13,16-17,19-20H2/t22-,23+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.51E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484054 ((S)-1-((S)-8-(4'-(2- aminoethyl)biphenyl-3- ylsulf...) Show SMILES NCCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C35H45N3O8S2/c36-16-11-26-7-9-27(10-8-26)28-3-1-6-33(19-28)48(43,44)38-17-14-34(15-18-38)21-29(23-46-34)37-22-30(40)24-45-31-4-2-5-32(20-31)47(41,42)35(25-39)12-13-35/h1-10,19-20,29-30,37,39-40H,11-18,21-25,36H2/t29-,30-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.62E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484069 (3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...) Show SMILES CCn1cc(c(=O)c2ccccc12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2CC2)CC1 |r| Show InChI InChI=1S/C31H39N3O8S2/c1-2-33-19-29(30(36)27-8-3-4-9-28(27)33)44(39,40)34-14-12-31(13-15-34)17-22(20-42-31)32-18-23(35)21-41-24-6-5-7-26(16-24)43(37,38)25-10-11-25/h3-9,16,19,22-23,25,32,35H,2,10-15,17-18,20-21H2,1H3/t22-,23+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.65E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484065 ((S)-l-(3-(l- (hydroxymethyl) cyclopropylsulfonyl) ...) Show SMILES CCCNCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C37H49N3O8S2/c1-2-17-38-23-28-9-11-29(12-10-28)30-5-3-8-35(20-30)50(45,46)40-18-15-36(16-19-40)22-31(25-48-36)39-24-32(42)26-47-33-6-4-7-34(21-33)49(43,44)37(27-41)13-14-37/h3-12,20-21,31-32,38-39,41-42H,2,13-19,22-27H2,1H3/t31-,32-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.78E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484055 ((S)-1-((R)-8-(4'-(1- aminocyclopropyl)-6- fluorobi...) Show SMILES NC1(CC1)c1ccc(cc1)-c1cc(ccc1F)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C36H44FN3O8S2/c37-33-9-8-31(19-32(33)25-4-6-26(7-5-25)36(38)12-13-36)50(45,46)40-16-14-34(15-17-40)20-27(22-48-34)39-21-28(42)23-47-29-2-1-3-30(18-29)49(43,44)35(24-41)10-11-35/h1-9,18-19,27-28,39,41-42H,10-17,20-24,38H2/t27-,28+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.84E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484077 (3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...) Show SMILES Cc1cccc2c(O)c(cnc12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2CC2)CC1 |r| Show InChI InChI=1S/C30H37N3O8S2/c1-20-4-2-7-26-28(20)32-17-27(29(26)35)43(38,39)33-12-10-30(11-13-33)15-21(18-41-30)31-16-22(34)19-40-23-5-3-6-25(14-23)42(36,37)24-8-9-24/h2-7,14,17,21-22,24,31,34H,8-13,15-16,18-19H2,1H3,(H,32,35)/t21-,22+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.89E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484078 (3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...) Show SMILES O[C@@H](CN[C@H]1COC2(C1)CCN(CC2)S(=O)(=O)c1cnc2cc(F)ccc2c1O)COc1cccc(c1)S(=O)(=O)C1CC1 |r| Show InChI InChI=1S/C29H34FN3O8S2/c30-19-4-7-25-26(12-19)32-16-27(28(25)35)43(38,39)33-10-8-29(9-11-33)14-20(17-41-29)31-15-21(34)18-40-22-2-1-3-24(13-22)42(36,37)23-5-6-23/h1-4,7,12-13,16,20-21,23,31,34H,5-6,8-11,14-15,17-18H2,(H,32,35)/t20-,21+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.95E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484079 (1-ethyl-8-fluoro-3-((R)- 3-((S)-2-hydroxy-3-(3- (i...) Show SMILES CCn1cc(c(=O)c2cccc(F)c12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C(C)C)CC1 |r| Show InChI InChI=1S/C31H40FN3O8S2/c1-4-34-18-28(30(37)26-9-6-10-27(32)29(26)34)45(40,41)35-13-11-31(12-14-35)16-22(19-43-31)33-17-23(36)20-42-24-7-5-8-25(15-24)44(38,39)21(2)3/h5-10,15,18,21-23,33,36H,4,11-14,16-17,19-20H2,1-3H3/t22-,23+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484062 ((S)-1-((S)-8-(4'-((tert- butylamino(methyl) biphen...) Show SMILES CC(C)(C)NCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C38H51N3O8S2/c1-36(2,3)40-23-28-10-12-29(13-11-28)30-6-4-9-35(20-30)51(46,47)41-18-16-37(17-19-41)22-31(25-49-37)39-24-32(43)26-48-33-7-5-8-34(21-33)50(44,45)38(27-42)14-15-38/h4-13,20-21,31-32,39-40,42-43H,14-19,22-27H2,1-3H3/t31-,32-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.17E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484056 ((S)-1-((S)-8-(4'-(1- aminocyclopropyl)-6- methoxyb...) Show SMILES COc1ccc(cc1-c1ccc(cc1)C1(N)CC1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C37H47N3O9S2/c1-47-34-10-9-32(20-33(34)26-5-7-27(8-6-26)37(38)13-14-37)51(45,46)40-17-15-35(16-18-40)21-28(23-49-35)39-22-29(42)24-48-30-3-2-4-31(19-30)50(43,44)36(25-41)11-12-36/h2-10,19-20,28-29,39,41-42H,11-18,21-25,38H2,1H3/t28-,29-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.31E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484044 ((2S)-1-(3-(2- hydroxyethylsulfonyl) phenoxy)-3-(8-...) Show SMILES OCCS(=O)(=O)c1cccc(OC[C@@H](O)CNC2COC3(C2)CCN(CC3)S(=O)(=O)c2ccc3ccccc3c2)c1 |r| Show InChI InChI=1S/C29H36N2O8S2/c32-14-15-40(34,35)27-7-3-6-26(17-27)38-21-25(33)19-30-24-18-29(39-20-24)10-12-31(13-11-29)41(36,37)28-9-8-22-4-1-2-5-23(22)16-28/h1-9,16-17,24-25,30,32-33H,10-15,18-21H2/t24?,25-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.33E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484067 ((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...) Show SMILES COCCNCc1ccc(cc1)-c1cccc(c1)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@H](O)COc2cccc(c2)S(=O)(=O)C2(CO)CC2)CC1 |r| Show InChI InChI=1S/C37H49N3O9S2/c1-47-19-16-38-23-28-8-10-29(11-9-28)30-4-2-7-35(20-30)51(45,46)40-17-14-36(15-18-40)22-31(25-49-36)39-24-32(42)26-48-33-5-3-6-34(21-33)50(43,44)37(27-41)12-13-37/h2-11,20-21,31-32,38-39,41-42H,12-19,22-27H2,1H3/t31-,32-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.35E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484064 ((S)-1-((S)-8-(4'- (azetidin-1- ylmethyl)biphenyl-3...) Show SMILES OCC1(CC1)S(=O)(=O)c1cccc(OC[C@@H](O)CN[C@@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cccc(c2)-c2ccc(CN3CCC3)cc2)c1 |r| Show InChI InChI=1S/C37H47N3O8S2/c41-27-37(12-13-37)49(43,44)34-6-2-5-33(21-34)47-26-32(42)23-38-31-22-36(48-25-31)14-18-40(19-15-36)50(45,46)35-7-1-4-30(20-35)29-10-8-28(9-11-29)24-39-16-3-17-39/h1-2,4-11,20-21,31-32,38,41-42H,3,12-19,22-27H2/t31-,32-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.50E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484072 (1-ethyl-3-((R)-3-((S)-2- hydroxy-3-(3- (methylsulf...) Show SMILES CCn1cc(c(=O)c2ccccc12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COc2cccc(c2)S(C)(=O)=O)CC1 |r| Show InChI InChI=1S/C29H37N3O8S2/c1-3-31-18-27(28(34)25-9-4-5-10-26(25)31)42(37,38)32-13-11-29(12-14-32)16-21(19-40-29)30-17-22(33)20-39-23-7-6-8-24(15-23)41(2,35)36/h4-10,15,18,21-22,30,33H,3,11-14,16-17,19-20H2,1-2H3/t21-,22+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid UniChem	US Patent	n/a	n/a	3.77E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484046 (2-(3-((S)-2-hydroxy-3- ((R)-8-(quinolin-3- ylsulfo...) Show SMILES NC(=O)CS(=O)(=O)c1cccc(OC[C@@H](O)CN[C@H]2COC3(C2)CCN(CC3)S(=O)(=O)c2cnc3ccccc3c2)c1 |r| Show InChI InChI=1S/C28H34N4O8S2/c29-27(34)19-41(35,36)24-6-3-5-23(13-24)39-18-22(33)15-30-21-14-28(40-17-21)8-10-32(11-9-28)42(37,38)25-12-20-4-1-2-7-26(20)31-16-25/h1-7,12-13,16,21-22,30,33H,8-11,14-15,17-19H2,(H2,29,34)/t21-,22+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.32E+4	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair
Beta-3 adrenergic receptor (Homo sapiens (Human))	BDBM484068 (1-ethyl-3-((S)-3-((R)-2- hydroxy-3-(3- (methylsulf...) Show SMILES CCn1cc(c(=O)c2ccccc12)S(=O)(=O)N1CCC2(C[C@@H](CO2)NC[C@@H](O)COc2cccc(c2)S(C)(=O)=O)CC1 |r| Show InChI InChI=1S/C29H37N3O8S2/c1-3-31-18-27(28(34)25-9-4-5-10-26(25)31)42(37,38)32-13-11-29(12-14-32)16-21(19-40-29)30-17-22(33)20-39-23-7-6-8-24(15-23)41(2,35)36/h4-10,15,18,21-22,30,33H,3,11-14,16-17,19-20H2,1-2H3/t21-,22+/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.07E+5	n/a	n/a	n/a	n/a	n/a	n/a
Arena Pharmaceuticals, Inc. US Patent					Assay Description Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...				US Patent US10927123 (2021) BindingDB Entry DOI: 10.7270/Q2D221QM
					More data for this Ligand-Target Pair